New ProFound AI risk software, offering a 2-year projected
risk score to be featured


NASHUA, N.H. – January
6, 2021 – iCAD,
(NASDAQ: ICAD), a global medical technology leader providing innovative
cancer detection and therapy solutions, today announced that it will participate in
the 10th Annual LifeSci Partners Corporate Access
Event, January 6-8 and 11-14, 2021.


Michael Klein,
Chairman and CEO, will host 1×1 meetings and will participate in a panel, Innovations
in Cancer Diagnostics, on Thursday, January 7th at 4pm EST.


Mr. Klein’s focus in diagnostics will be on iCAD’s newly
launched ProFound AI Risk offering. This new breast cancer screening capability
is the first and only commercially available clinical decision support tool
that provides an accurate 2-year risk estimation based solely on a screening
mammogram. Compelling research published in Radiology
concluded that the ProFound AI Risk model is effective at identifying women at
high likelihood of being diagnosed with breast cancer within two years of a
negative screening mammogram and in possible need of supplemental screening.


To register to listen to the presentation or to request a
meeting, visit:



About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a
global medical technology leader providing innovative cancer detection and
therapy solutions. For more information, visit


Harbor” Statement under the Private Securities Litigation Reform Act of

statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. For example, when the Company discusses
the potential of ProFound AI Risk and its relationship with Change Healthcare, the
benefits of the Company’s products,
and clinical plans and updates, it is using forward-looking statements.  Such forward-looking statements involve a
number of known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the Company to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Such factors include,
but are not limited, to the Company’s ability to achieve business and strategic
objectives, increase sales and acceptance of products, adoption by CMS of a new
payment model, and that such model will prove beneficial to the Company, which
is not assured, implement expansion plans, the risks of uncertainty of patent
protection, the impact of supply and manufacturing constraints or difficulties,
uncertainty of future sales levels, protection of patents and other proprietary
rights, the impact of supply and manufacturing constraints or difficulties,
product market acceptance, possible technological obsolescence of products,
increased competition, to successfully defend itself in litigation matters, government
regulation, changes in Medicare or other reimbursement policies, risks relating
to our existing and future debt obligations, competitive factors, the effects
of a decline in the economy or markets served by the Company; the effects of a global
pandemic, and other risks detailed in the Company’s filings with the Securities
and Exchange Commission. The words “believe,” “demonstrate,” “intend,”
“expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and
similar expressions identify forward-looking statements. Readers are cautioned
not to place undue reliance on those forward-looking statements, which speak
only as of the date the statement was made. The Company is under no obligation
to provide any updates to any information contained in this release. For
additional disclosure regarding these and other risks faced by iCAD, please see
the disclosure contained in our public filings with the Securities and Exchange
Commission, available on the Investors section of our website at
and on the SEC’s website at





Cook, iCAD 




Feffer, LifeSci Advisors